Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Novel bh3 mimetic peptide compound targeting ptp1b and its preparation method and application

A technology of compound and mimetic peptide, which is applied in the field of new BH3 mimetic compound and its preparation, can solve the problem of compound difficulty and achieve the effect of excellent development prospect

Active Publication Date: 2022-04-01
OCEAN UNIV OF CHINA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] Summarizing and analyzing the development status of PTP1B organic small molecule inhibitors, it can be found that the development of PTP1B small molecule inhibitors suffers from two points: ① The selectivity of PTP1B inhibitors: PTP1B is highly homologous to other protein phosphatases such as TCPTP, especially the activity The site homology is as high as 94%; ②PTP1B inhibitor membrane penetration ability: PTP1B catalyzes protein phosphorylation and the active site is charged, so compounds with PTP1B inhibitory activity are charged or strongly polar; and PTP1B is distributed in the cell membrane Intrinsic, charged or highly polar compounds have difficulty crossing cell membranes to act

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel bh3 mimetic peptide compound targeting ptp1b and its preparation method and application
  • Novel bh3 mimetic peptide compound targeting ptp1b and its preparation method and application
  • Novel bh3 mimetic peptide compound targeting ptp1b and its preparation method and application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0035] 1. The specific preparation process of Pal-PUMA is as follows:

[0036] (1) Resin activation: at room temperature, weigh the corresponding amount of Fmoc-Phe-Wang resin, wash it with dichloromethane (DCM) 4 times, place it in a manual polypeptide solid-phase synthesizer, add 5ml DCM to swell and activate it for 3 hours, and dimethicone Washed 4 times with methyl formamide (DMF), added 20% piperidine DMF to remove the Fmoc protecting group for 20 min, washed 4 times with 5ml DMF, washed 4 times with 5ml DCM, and tested with Kaiser's reagent.

[0037] (2) Connecting Leu(L): DMF was washed 3 times, Fmoc-Leu-OH, HBTU, HOBt and 6 times the resin molar weight of DIEA were added respectively, dissolved in 10ml DMF, stirred at room temperature for 2 hours , washed 4 times with DMF, added 20% piperidine DMF to remove the Fmoc protecting group for 20 min, washed 4 times with 5ml DMF, washed 4 times with 5ml DCM, and detected by Kaiser's reagent.

[0038] (3) Asp(D) connection: w...

Embodiment 2

[0053] The mass spectrum data and HPLC purity analysis data of the eight BH3 mimetic peptide compounds are shown in Table 1.

[0054] Table 1. Mass Spectrometry Data and HPLC Purity Analysis Data of BH3 Mimetic Peptides

[0055]

Embodiment 3

[0056] Example 3, Determination of protein tyrosine phospholipase 1B (PTP1B) inhibitory activity

[0057] In the present invention, MES buffer is adopted as the reaction system, human protein tyrosine phosphatase 1B (PTP1B) is utilized, disodium p-nitrophenylphosphate (pNPP) is used as the specific substrate, and sodium orthovanadate is selected as the positive drug , With DMSO as negative control, a screening model based on enzyme reaction rate of 96-well microplate as carrier was established, and PTP1B inhibitors were found by enzymatic methods.

[0058] The specific implementation method is: using MES buffer system (25mM, pH6.5), sequentially add 10μL pNPP (77mM), 86μL MES buffer solution, 4μL compound (2mM compound mother solution dissolved in DMSO), 100μL PTP1B solution ( 50 nM), the total reaction volume was 200 μL. 3 parallels in each group, with DMSO as the negative control and sodium orthovanadate (2mM) as the positive control, at 25°C, shake on the shaker for 1min, ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a novel BH3 mimetic peptide compound targeting PTP1B and its preparation method and application. The structural formula of the BH3 mimetic peptide compound is as follows: the amino acids in the structure of the BH3 mimetic peptide compound are all natural amino acids, and the peptide N-terminus of chain with R 1 The groups are linked by amide bonds, R 1 is carboxylic acid or dicarboxylic acid, R 2 is OH or NH 2 . The peptidomimetic compound is derived from the core region of the BH3 domain of the Bcl-2 anti-apoptotic protein, and is prepared by a polypeptide solid-phase synthesis method. The present invention proves through experiments that the BH3 mimetic peptide compound can significantly inhibit the activity of protein tyrosine phosphorylase 1B (PTP1B), and is effective in treating diseases related to PTP1B, such as diabetes, cancer, Alzheimer's disease, etc. It has potential application value in drug development.

Description

technical field [0001] The invention belongs to the field of biomedicine, and specifically relates to a novel BH3 mimetic compound targeting PTP1B and its preparation method and application. Background technique [0002] Protein tyrosine phosphatase 1B (protein tyrosine phosphatase 1B, PTP1B) was successfully isolated and identified as early as 1988. A large number of follow-up research results have shown that the excessive and abnormal expression of PTP1B is closely related to the onset and development of T2DM obesity . PTP1B is a novel potential target for the treatment of T2DM and obesity. PTP1B is a key negative regulatory protein in the insulin signal transduction pathway. PTP1B inhibitors block the insulin-stimulated insulin receptor (IR) tyrosine phosphorylation, thereby affecting the insulin receptor substrate (IRS-1) Phosphorylation, insulin-like and insulin-sensitizing, improving insulin resistance, lowering blood sugar. At the same time, it can enhance the sign...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/08C07K1/08C07K1/06C07K1/20A61K38/10A61P35/00A61P25/28A61P3/10
CPCA61P3/10A61P25/28A61P35/00C07K7/08A61K38/00Y02P20/55
Inventor 张传亮王树林路晓吴丽娟
Owner OCEAN UNIV OF CHINA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com